Australia's most trusted
source of pharma news
Sunday, 08 September 2024
Posted 26 July 2024 PM
Two companies are looking to almost triple their earnings by the end of this decade and our readers wanted to know who - and how - in our top read story this week.
With the obesity juggernaut showing no sign of slowing down, it's perhaps not surprising that Novo Nordisk and Eli Lilly are expected to top the earnings list, according to analysts at Evaluate. It's described as quite the "turn of the tables" given neither company had even made the Top 10 until last year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.